Senseonics Holdings (SENS) just posted its FY 2025 third quarter numbers, with revenue at US$8.1 million and a basic EPS loss of US$0.43, while net income excluding extra items came in at a loss of US$19.5 million. The company has seen quarterly revenue move from US$4.3 million in Q3 2024 to US$8.1 million in Q3 2025, alongside quarterly basic EPS shifting from a loss of US$0.77 to a loss of US$0.43 over the same stretch. For investors, this set of results puts the focus squarely on how quickly margins can tighten up against a backdrop of ongoing losses.
See our full analysis for Senseonics Holdings.With the headline figures on the table, the next step is to see how these results line up with the widely held narratives around Senseonics, highlighting where the growth story and the profitability concerns intersect or pull apart.
See what the community is saying about Senseonics Holdings
Losses Still Heavy At US$63.8 Million TTM
- On a trailing twelve month basis, Senseonics reported US$29.3 million in revenue against a net loss of US$63.8 million and basic EPS of US$1.65 in losses, so the business is still firmly loss making even as sales have scaled.
- Bears point out that even with this revenue base, forecasts still do not show profitability within the next three years, and the latest quarterly losses of US$19.5 million keep that concern very visible.
- That quarterly loss compares with trailing twelve month losses of US$63.8 million, so a single quarter is absorbing a sizeable share of the full year loss profile.
- Critics also highlight that consensus expects revenue to grow at 32.4% a year while profitability remains out of reach, which is why they question how quickly these losses can shrink in a meaningful way.
Revenue Momentum Versus 32.4% Growth Outlook
- Quarterly revenue has moved from US$4.3 million in Q3 2024 to US$8.1 million in Q3 2025, and analysts are forecasting around 32.4% annual revenue growth, which is materially faster than the 10.2% outlook cited for the wider US market.
- Bulls argue that this kind of top line profile, helped by rising CGM adoption and new product plans, could eventually support better margins than the recent net loss of US$19.5 million suggests.
- Supporters often point to falling trailing twelve month losses from US$80.5 million in mid 2024 to US$63.8 million by Q3 2025, alongside higher trailing twelve month revenue of US$29.3 million, as evidence that scale is gradually helping.
- At the same time, the fact that forecasts still show the company remaining unprofitable over the next three years is the main tension in the bullish story, because it means the stronger revenue outlook has yet to translate into a clear earnings path.
P/S Multiple Of 9.5x Demands Execution
- SENS trades on a P/S ratio of 9.5x compared with 4x for peers and 2.9x for the broader US Medical Equipment industry, so investors are paying more than double the sector multiple for each dollar of current revenue.
- Consensus narrative suggests that this premium is being supported by strong product momentum and a forecast revenue growth rate of 32.4% a year, but the same analysis still flags ongoing losses and recent dilution as key pressure points.
- Shareholders have already seen their stakes diluted over the past year, and analysts expect share count to rise by around 7% a year for three years, which can cap per share benefits even if revenue scales as expected.
- With net income excluding extra items at a loss of US$19.5 million in Q3 2025 and trailing twelve month losses of US$63.8 million, the current valuation rests on the idea that this premium P/S multiple remains acceptable while the company works through a multi year loss profile.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Senseonics Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
If you are unsure whether the balance of risks and rewards here truly matches your own comfort level, take a moment to review the full picture for yourself, including 2 key rewards and 2 important warning signs.
See What Else Is Out There
You are looking at a business with US$63.8 million in trailing losses, ongoing quarterly losses and a premium 9.5x P/S that all keep risk firmly in view.
If that mix of heavy losses and valuation risk feels uncomfortable, you might want to balance it by checking out 75 resilient stocks with low risk scores that focus on steadier, lower risk profiles right now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com